Does Treatment Differ for Older Patients?

Half of adult patients diagnosed with non-Hodgkin lymphoma are over age 60--oncologists must take into account age and associated complications. 

PUBLISHED: 3:41 PM, FRI MARCH 13, 2009
Talk about this article with other patients, caregivers, and advocates in the General Discussions CURE discussion group.
Of all adult patients diagnosed with non-Hodgkin lymphoma, half are over the age of 60. Plus, statistics show that as life expectancy increases, the incidence of NHL in the older population is rising. These patients present an especially difficult challenge to oncologists, who must take into account age and associated complications.

Those complications may include one or more other diseases that elderly patients often have in addition to lymphoma. Older patients also tend to have reduced kidney and liver functions, possibly restricting a drug’s effectiveness and the patient’s ability to pro­cess and excrete the drug. As a result, side effects—especially infections and low blood counts—may be more severe.

Rituxan (rituximab) plus the chemotherapy regimen known as CHOP is generally well tolerated, says Owen O’Connor, MD. “But we know that people who are older don’t have as easy a time with these drugs, and we often have to reduce the doses,” he says. Side effects can be lessened by co-treatment with a compound called granulocyte colony-stimulating factor, which is naturally found in the body and stimulates the growth of blood cells.

Increased toxicity is one reason stem cell transplantations are often not recommended for older patients, as the high doses of radiation or chemotherapy that precede the transplant are often poorly tolerated. But recent studies have shown that lower doses of radiation can reduce transplant-related toxicity and still be effective. (Read about the latest advances in stem cell transplantation in CURE’s “Where Are We Now?” special issue from 2008.)

In one study of patients with leukemia, although the rate of relapse was higher in patients who received low-dose radiation than those who received higher doses (41 percent compared with 24 percent), overall survival was comparable. Other studies suggest older patients rival their younger counterparts when it comes to quality of life after a transplant.

One way physicians manage older patients is to suggest safer, less toxic options. Treanda (bendamustine), for example, appears to be better tolerated than CHOP with comparable efficacy. Or chemotherapy might be foregone altogether in favor of biological therapies such as Revlimid (lenalidomide), a multiple myeloma drug being investigated for treating NHL, or Zolinza (vorinostat), an epigenetic agent approved for T-cell lymphoma.

Unfortunately, reduced toxicity often comes at the cost of effectiveness in traditional dosing and scheduling. “Quality of life is obviously the issue,” says Bart Kamen, MD, PhD. “An additional six to eight months of high-quality time can be a lot.” To provide tumor control with less toxicity, Kamen says physicians are now experimenting with lower doses at a more frequent schedule, known as metronomic therapy.

Muddying the waters further is that most clinical trials are done in patients younger than 60, whereas most NHL patients are between 65 and 75.

“What works on a 60-year-old may not work on a patient who is 70,” says Kamen. Some recent trials examined the success of different treatment strategies for aggressive lymphomas specifically in older patient populations and found that R-CHOP improved survival rates compared with CHOP alone in patients between ages 60 and 80.

Talk about this article with other patients, caregivers, and advocates in the General Discussions CURE discussion group.
Special Feature
Share Your Art
Related Articles
Transplants and Triathlons: An Unwelcome Tradition
Two transplants, three mini triathons. Running the race for myself and others shows how lessons learned in the hospital translate to victory on the outside.
Early Data Suggest Promise for Immunotherapies in Lymphomas
Questions persist regarding mechanisms of PD-L1 overexpression in lymphoid malignancies, patient selection, biomarkers to guide therapy and predict response, and identification of agents to use in combination with PD-1/PD-L1 inhibitors.
Presenting Emil Parente: Living With WM For 32 Years
Emil Parente is a WMer with a real past, and he is happy to share it with others, particularly those who are newly diagnosed.
Related Videos
Susan Thornton on Unmet Needs in Cutaneous Lymphoma
Susan Thornton provides an overview of the unmet needs in cutaneous lymphoma.
Susan Thornton on Bridging the Knowledge Gap Between Researchers and Patients
Susan Thornton discusses her story and her efforts to bridge the knowledge gap between researchers and patients.
Dr. Adam Asch Encourages Lymphoma Patients to Fully Understand Their Diagnosis
Adam Asch, senior deputy director of Stephenson Cancer Center, gives advice to patients after they have been diagnosed with lymphoma.